149 related articles for article (PubMed ID: 27154979)
1. Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance.
Seebacher N; Lane DJ; Richardson DR; Jansson PJ
Free Radic Biol Med; 2016 Jul; 96():432-45. PubMed ID: 27154979
[TBL] [Abstract][Full Text] [Related]
2. Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones.
Al-Akra L; Bae DH; Sahni S; Huang MLH; Park KC; Lane DJR; Jansson PJ; Richardson DR
J Biol Chem; 2018 Mar; 293(10):3562-3587. PubMed ID: 29305422
[TBL] [Abstract][Full Text] [Related]
3. Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter.
Seebacher NA; Lane DJ; Jansson PJ; Richardson DR
J Biol Chem; 2016 Feb; 291(8):3796-820. PubMed ID: 26601947
[TBL] [Abstract][Full Text] [Related]
4. Oxidative Stress Promotes Doxorubicin-Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions.
Pinzón-Daza ML; Cuellar-Saenz Y; Nualart F; Ondo-Mendez A; Del Riesgo L; Castillo-Rivera F; Garzón R
J Cell Biochem; 2017 Jul; 118(7):1868-1878. PubMed ID: 28106284
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration.
Yamagishi T; Sahni S; Sharp DM; Arvind A; Jansson PJ; Richardson DR
J Biol Chem; 2013 Nov; 288(44):31761-71. PubMed ID: 24062304
[TBL] [Abstract][Full Text] [Related]
6. A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC.
Seebacher NA; Richardson DR; Jansson PJ
Cell Death Dis; 2016 Dec; 7(12):e2510. PubMed ID: 27906178
[TBL] [Abstract][Full Text] [Related]
7. Glucose modulation induces reactive oxygen species and increases P-glycoprotein-mediated multidrug resistance to chemotherapeutics.
Seebacher NA; Richardson DR; Jansson PJ
Br J Pharmacol; 2015 May; 172(10):2557-72. PubMed ID: 25586174
[TBL] [Abstract][Full Text] [Related]
8. Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).
Jansson PJ; Yamagishi T; Arvind A; Seebacher N; Gutierrez E; Stacy A; Maleki S; Sharp D; Sahni S; Richardson DR
J Biol Chem; 2015 Apr; 290(15):9588-603. PubMed ID: 25720491
[TBL] [Abstract][Full Text] [Related]
9. Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance.
Stacy AE; Palanimuthu D; Bernhardt PV; Kalinowski DS; Jansson PJ; Richardson DR
J Med Chem; 2016 Sep; 59(18):8601-20. PubMed ID: 27524608
[TBL] [Abstract][Full Text] [Related]
10. Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells.
Kopecka J; Campia I; Jacobs A; Frei AP; Ghigo D; Wollscheid B; Riganti C
Oncotarget; 2015 Mar; 6(9):6776-93. PubMed ID: 25686827
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Nooter K; Stoter G
Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
[TBL] [Abstract][Full Text] [Related]
12. Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells.
Wen Y; Zhao RQ; Zhang YK; Gupta P; Fu LX; Tang AZ; Liu BM; Chen ZS; Yang DH; Liang G
Oncotarget; 2017 May; 8(18):29760-29770. PubMed ID: 28423656
[TBL] [Abstract][Full Text] [Related]
13. Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha.
Riganti C; Doublier S; Aldieri E; Orecchia S; Betta PG; Gazzano E; Ghigo D; Bosia A
Eur Respir J; 2008 Aug; 32(2):443-51. PubMed ID: 18385176
[TBL] [Abstract][Full Text] [Related]
14. Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells.
Kim H; Barroso M; Samanta R; Greenberger L; Sztul E
Am J Physiol; 1997 Aug; 273(2 Pt 1):C687-702. PubMed ID: 9277367
[TBL] [Abstract][Full Text] [Related]
15. Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein.
Abd-Ellatef GEF; Gazzano E; El-Desoky AH; Hamed AR; Kopecka J; Belisario DC; Costamagna C; S Marie MA; Fahmy SR; Abdel-Hamid AZ; Riganti C
Pharmacol Res; 2022 Jan; 175():105975. PubMed ID: 34785319
[TBL] [Abstract][Full Text] [Related]
16. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast.
Doublier S; Belisario DC; Polimeni M; Annaratone L; Riganti C; Allia E; Ghigo D; Bosia A; Sapino A
BMC Cancer; 2012 Jan; 12():4. PubMed ID: 22217342
[TBL] [Abstract][Full Text] [Related]
17. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
18. Subcellular localization and activity of multidrug resistance proteins.
Rajagopal A; Simon SM
Mol Biol Cell; 2003 Aug; 14(8):3389-99. PubMed ID: 12925771
[TBL] [Abstract][Full Text] [Related]
19. Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.
Riganti C; Doublier S; Viarisio D; Miraglia E; Pescarmona G; Ghigo D; Bosia A
Br J Pharmacol; 2009 Apr; 156(7):1054-66. PubMed ID: 19298255
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract.
Plouzek CA; Ciolino HP; Clarke R; Yeh GC
Eur J Cancer; 1999 Oct; 35(10):1541-5. PubMed ID: 10673984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
